Martin H Ellis1, Maya Koren-Michowitz2, Noa Lavi3, Alessandro M Vannucchi4, Ruben Mesa5, Claire N Harrison6. 1. Hematology Institute, Meir Medical Center, Kfar Saba, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: martinel@clalit.org.il. 2. Department of Hematology, Asaf HaRofeh Medical Center, Tzrifin, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Rambam Medical Center, Haifa, Israel; Bruce Rappoport Faculty of Medicine, Technion, Haifa, Israel. 4. Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. 5. Department of Hematology, Mayo Clinic Scottsdale, AZ, USA. 6. Department of Haematology, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom.
Abstract
BACKGROUND: Ruxolitinib is established as treatment for symptomatic myeloproliferative neoplasm (MPN)-associated myelofibrosis. The strict inclusion and exclusion criteria and dose modification rules that applied to the COMFORTI and II studies that led to the licensing of ruxolitinib are not always applicable to routine clinical practice. Thus physicians now face decisions regarding ruxolitinib use that were not addressed in these pivotal trials. METHODS: We performed an online survey of hematologists practicing in Europe, Israel, the United Kingdom and the United States. Demographic details regarding the physicians and their practice as relates to MPNs were collected. Management decisions pertaining to the use of ruxolitinib were obtained regarding 10 clinical scenarios relating to anemia, thrombocytopenia, frailty, infection and lack or loss of response to ruxolitnib in MF patients. RESULTS: 140 physicians responded to the survey. There were marked differences regarding their decisions for ruxolitinib administration in MF patients with or developing anemia or thrombocytopenia. Similarly there was little consensus regarding management of patients refractory or losing a response to ruxolitinib. There were differences between "MPN-focused" and "non-MPN-focused" physicians in certain areas. CONCLUSION: Physician practices regarding management of MF patients experiencing ruxolitinib-related toxicities or in whom response to the drug is lost was variable. This was true of "MPN-focused" and "non-MPN-focused" physicians in certain cases. Physician education and experience in using ruxolitinib may improve patient management.
BACKGROUND:Ruxolitinib is established as treatment for symptomatic myeloproliferative neoplasm (MPN)-associated myelofibrosis. The strict inclusion and exclusion criteria and dose modification rules that applied to the COMFORTI and II studies that led to the licensing of ruxolitinib are not always applicable to routine clinical practice. Thus physicians now face decisions regarding ruxolitinib use that were not addressed in these pivotal trials. METHODS: We performed an online survey of hematologists practicing in Europe, Israel, the United Kingdom and the United States. Demographic details regarding the physicians and their practice as relates to MPNs were collected. Management decisions pertaining to the use of ruxolitinib were obtained regarding 10 clinical scenarios relating to anemia, thrombocytopenia, frailty, infection and lack or loss of response to ruxolitnib in MF patients. RESULTS: 140 physicians responded to the survey. There were marked differences regarding their decisions for ruxolitinib administration in MF patients with or developing anemia or thrombocytopenia. Similarly there was little consensus regarding management of patients refractory or losing a response to ruxolitinib. There were differences between "MPN-focused" and "non-MPN-focused" physicians in certain areas. CONCLUSION: Physician practices regarding management of MF patients experiencing ruxolitinib-related toxicities or in whom response to the drug is lost was variable. This was true of "MPN-focused" and "non-MPN-focused" physicians in certain cases. Physician education and experience in using ruxolitinib may improve patient management.
Authors: A M Vannucchi; T Barbui; F Cervantes; C Harrison; J-J Kiladjian; N Kröger; J Thiele; C Buske Journal: Ann Oncol Date: 2015-08-04 Impact factor: 32.976
Authors: Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245
Authors: Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245
Authors: Haifa Kathrin Al-Ali; Martin Griesshammer; Philipp le Coutre; Cornelius F Waller; Anna Marina Liberati; Philippe Schafhausen; Renato Tavares; Pilar Giraldo; Lynda Foltz; Pia Raanani; Vikas Gupta; Bayane Tannir; Julian Perez Ronco; Jagannath Ghosh; Bruno Martino; Alessandro M Vannucchi Journal: Haematologica Date: 2016-05-31 Impact factor: 9.941
Authors: M Marchetti; G Barosi; F Cervantes; G Birgegård; M Griesshammer; C Harrison; R Hehlmann; J-J Kiladjian; N Kröger; M F McMullin; F Passamonti; A Vannucchi; T Barbui Journal: Leukemia Date: 2016-10-14 Impact factor: 11.528
Authors: Martin H Ellis; Noa Lavi; Elena Mishchenko; Najib Dally; David Lavie; Anna Courevitch; Odit Gutwein; Shlomo Bulvik; Andrei Braester; Evgeni Chubar; Sigal Tavor; Adrian Duek; Ilya Kirgner; Maya Koren-Michowitz Journal: Leuk Res Date: 2015-08-12 Impact factor: 3.156
Authors: John T Reilly; Mary Frances McMullin; Philip A Beer; Nauman Butt; Eibhlin Conneally; Andrew S Duncombe; Anthony R Green; George Mikhaeel; Marie H Gilleece; Steven Knapper; Adam J Mead; Ruben A Mesa; Mallika Sekhar; Claire N Harrison Journal: Br J Haematol Date: 2014-06-25 Impact factor: 6.998
Authors: C N Harrison; A M Vannucchi; J-J Kiladjian; H K Al-Ali; H Gisslinger; L Knoops; F Cervantes; M M Jones; K Sun; M McQuitty; V Stalbovskaya; P Gopalakrishna; T Barbui Journal: Leukemia Date: 2016-05-23 Impact factor: 11.528
Authors: Simona Stivala; Tamara Codilupi; Sime Brkic; Anne Baerenwaldt; Nilabh Ghosh; Hui Hao-Shen; Stephan Dirnhofer; Matthias S Dettmer; Cedric Simillion; Beat A Kaufmann; Sophia Chiu; Matthew Keller; Maria Kleppe; Morgane Hilpert; Andreas S Buser; Jakob R Passweg; Thomas Radimerski; Radek C Skoda; Ross L Levine; Sara C Meyer Journal: J Clin Invest Date: 2019-03-04 Impact factor: 14.808